Eikon Therapeutics, Inc. Common Stock (EIKN) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN US2825641036

Price
5.35 USD
Market cap
289.64 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
36.89 %
Return on assets (ROA)
-54.52 %

Eikon Therapeutics, Inc. Common Stock financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Gross profit–-24.18 m USD
Operating income-260.34 m USD-338.95 m USD
EBIT-243.78 m USD-323.41 m USD
Net income-243.81 m USD-324.25 m USD
Diluted EPS – continuing operations-4.52 USD-5.99 USD

Full history since 2023, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.